title: Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
abstract: BACKGROUND
  The aim of this phase II study was to evaluate the feasibility of a neoadjuvant chemotherapy regimen consisting of divided-dose docetaxel and cisplatin, with 5-fluorouracil (NAC-DCF), for treatment of patients with stage II/III squamous cell carcinoma of the esophagus (SCCE).
  
  
  METHODS
  The NAC-DCF regimen, consisting of 2-h infusion of docetaxel at 35 mg/m(2) on days 1 and 8, 4-h infusion of cisplatin at 12 mg/m(2) on days 1-5, and continuous infusion of 5-fluorouracil at 600 mg/m(2) on days 1-5, was administered. We compared NAC-DCF with conventional NAC-CF.
  
  
  RESULTS
  The DCF group comprised of 45 patients, and the CF group comprised of 28 patients. The incidence of grade 3/4 neutropenia was significantly higher in the DCF group (56%) than in the CF group (0%). Grade 2/3 pathological response was attained in a significantly higher percentage of patients in the DCF group (40%) than in the CF group (11%) (p=0.0153).
  
  
  CONCLUSIONS
  This DCF regimen led to a high frequency of pathological responses among patients with advanced SCCE.
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Toshiyasu
authors: T
authors: Ojima
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Mikihito
authors: M
authors: Nakamori
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Masaki
authors: M
authors: Nakamura
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Masahiro
authors: M
authors: Katsuda
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Keiji
authors: K
authors: Hayata
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Tomoya
authors: T
authors: Kato
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Junya
authors: J
authors: Kitadani
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Hirotaka
authors: H
authors: Tabata
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Akihiro
authors: A
authors: Takeuchi
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors: Makoto
authors: M
authors: Iwahashi
authors: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan yamaue-h@wakayama-med.ac.jp.
authors: Hiroki
authors: H
authors: Yamaue
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil
keywords: Esophageal cancer; cisplatin; docetaxel; fluorouracil; neoadjuvant chemotherapy